Bausch + Lomb (BLCO)

Executive Summary

Bausch + Lomb is a premier global eye health company with a comprehensive portfolio spanning contact lenses, lens care, pharmaceuticals, and surgical devices. With a history dating back to 1853, the company holds a strong market position in vision care, benefiting from secular growth in aging populations and increasing screen time. Recent financial performance has been stable, driven by robust demand for its consumer and surgical products. The company is well-positioned to capitalize on innovation, particularly in premium intraocular lenses and dry eye therapeutics. However, competitive pressures and pricing dynamics in the contact lens market remain headwinds. Management's focus on product launches and operational efficiency supports a positive outlook, though near-term growth may be tempered by macro uncertainties.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval of Presbyopia-Correcting Eye Drop (e.g., NOV03 for Dry Eye Relief)60% success
• Q2 2026Launch of Next-Generation Silicone Hydrogel Contact Lens80% success
• Q3 2026Q2 2026 Earnings Report (Potential Beat on Surgical Revenue)70% success